Selling Your Dental Practice to a DSO or DPO: The Math Behind Cash, Equity, Multiple Arbitrage, and Control
Dentistry’s consolidation debate is usually framed as a fight between independence and corporate dentistry. That framing is emotionally satisfying and financially incomplete. The more useful question for a practice owner is not whether DSOs are good or bad, or whether a newer Dental Partnership Organization is automatically better. It is whether a specific transaction leaves the dentist better off after accounting for cash, lost practice profits, taxes, work obligations, equity risk, control, and the eventual ability to turn private stock back into money.
That distinction came into sharp focus during an August 2026 episode of Just Say No To The DSO featuring Whitney Weiner, DDS, MS, Chief Growth Officer of ICON Dental Partners. Hosts Bob Spiel, MBA, and Nate Williams, CPA, CFP challenged ICON’s economics, particularly offers they said included only 20 to 30 percent cash at closing, substantial rollover equity, reduced post sale earnings, and multiyear work commitments. Weiner defended ICON as a doctor owned partnership model built to preserve clinical autonomy, reduce administrative burden, and allow dentists to participate in the value created as the organization grows. The debate was useful, but it also showed how quickly financial analysis can dissolve into competing narratives.
Both sides have incentives. ICON markets belonging, relief, autonomy, shared ownership, and the possibility of building something larger than one practice. Weiner is not an outside observer. Her role includes growth strategy and partnership development. Just Say No To The DSO is equally transparent about its starting position. The podcast describes dentistry as being under attack by corporations and exists to explain why selling to a DSO is often not as attractive as it sounds. Neither bias makes the underlying arguments false. It simply means dentists should listen to both with the same discipline they would use when evaluating a treatment plan proposed by someone who is also selling the procedure.
The first lesson is that the headline multiple is not the deal. A practice might be valued at six times normalized EBITDA, but that tells the owner very little unless the structure of the consideration is clear. Suppose a practice produces $500,000 of EBITDA after paying the dentist fair market clinical compensation. At six times EBITDA, the implied value is $3 million. If the seller receives 30 percent cash, that is $900,000 at closing, with $2.1 million represented by private company equity.
The critics are right to focus on what happens next. If the dentist previously received that $500,000 of owner profit each year and gives most of it up after the transaction, the cash received at closing equals only about 1.8 years of foregone ownership profit. For a dentist still producing heavily and expecting to work another five, ten, or fifteen years, that opportunity cost is enormous. But saying the dentist “sold the practice for 30 cents on the dollar” is also incomplete, because the remaining 70 percent was not necessarily surrendered. It was exchanged for equity.
That equity should not be treated as cash, and it should not be treated as worthless. Private company shares have value, but their value must be discounted for risks that do not exist with cash in the bank. The dentist needs to know what class of stock was received, what valuation was used, whether the shares can be diluted, whether debt sits ahead of the equity, whether distributions are being paid, what happens if the doctor cuts back clinically, whether shares can be clawed back, and exactly how retirement or redemption works. The critical calculation is the risk adjusted present value of the equity, including expected distributions and a probability weighted exit value.
ICON’s public materials make several claims that deserve to be taken seriously and verified in the legal documents. The company says partner dentists collectively own 90 percent of the holding company, management owns 10 percent, dentist equity sits at the same holding company level as executive equity, and six of seven board seats are held by doctors. ICON also says dentists retain contractual authority over clinical decisions, laboratories, supplies, schedules, hiring, firing, compensation, benefits, and staffing. If those rights are real, durable, and difficult to change without doctor approval, they are materially different from the structure of many investor controlled groups.
At the same time, collective ownership is not individual control. A dentist may be part of a class that owns 90 percent of a company while personally owning a very small fraction of it. That doctor may still have little direct influence over refinancing, new debt, stock issuance, a future sale, or the timing of a liquidity event. This is why the label DPO versus DSO matters far less than the documents underneath it. ICON itself acknowledges that the legal structure of a DPO resembles a DSO. The proposed difference is who owns the economics, who controls the board, and what rights remain with the dentist.
The 30 percent cash and 70 percent equity structure is not merely a criticism invented by the podcast. Gary DeWood, DDS, writing for The Pankey Institute, described two dentists who received 30 percent cash and rolled 70 percent into equity. He presented that structure as intentional. The theory is that the dentist does not simply cash out and become an employee. The dentist reinvests a large portion of practice value into the combined company and participates in future growth. That can be attractive, but only if the equity ultimately produces attractive value.
This brings the discussion to multiple arbitrage, one of the most misunderstood parts of the debate. In private equity, the term is legitimate. Academic and professional finance sources use “multiple arbitrage” to describe buying smaller businesses at lower EBITDA multiples and later having those earnings valued as part of a larger platform carrying a higher multiple. Research on 161 private equity buy and build transactions involving 971 add on acquisitions found that this sourcing effect was a meaningful contributor to returns. When researchers removed the benefit of acquiring smaller companies at cheaper multiples, much of the apparent performance advantage of buy and build strategies disappeared.
The mechanism is easy to see in dentistry. If a practice with $1 million of EBITDA is acquired at five times EBITDA, its independent enterprise value is $5 million. If that EBITDA becomes part of a platform later valued at ten times EBITDA, the same $1 million of earnings may support $10 million of enterprise value. That $5 million difference is the prize. But it does not automatically belong to the dentist. It may accrue to doctor shareholders, executives, investors, lenders, or some combination of them. It can also be consumed by corporate overhead, interest expense, integration problems, dilution, or a lower than expected exit multiple.
So Weiner was substantially correct that multiple arbitrage is a recognized financial concept. The podcast hosts were substantially correct that the outcome is not guaranteed. A five times practice does not become a ten times asset simply because a logo changes above the door. The platform must earn its premium through size, cash flow, management quality, diversification, integration, growth, and access to capital, and eventually someone must be willing to pay the higher multiple.
Recent dental M&A data reinforce that caution. Deal volume fell sharply in 2025 as higher borrowing costs and tighter financing exposed weaker acquisition strategies. Activity rebounded in 2026, and capital has begun flowing again, but investors appear more selective. The next wave of consolidation is less likely to reward growth for growth’s sake. Platforms will need strong cash collections, disciplined overhead, successful integration, manageable leverage, and durable doctor retention. For a dentist rolling substantial value into platform equity, those operational details matter as much as the purchase multiple.
Taxes are another area where slogans can obscure the real economics. A private practice sale is not simply taxed as ordinary income, nor is every dollar automatically taxed as a long term capital gain. The IRS treats the sale of a business as the sale of individual assets. Goodwill may receive favorable treatment, while depreciation recapture on equipment and other components can generate ordinary income. A later sale of holding company stock may produce capital gains, depending on structure and basis. The correct comparison is therefore not “50 percent tax versus 20 percent tax.” It is the after tax present value of both strategies.
For the practicing dentist, the most useful due diligence questions are remarkably practical. How much cash will I receive at closing. What annual owner profit am I giving up. What will I earn clinically afterward. How long must I work. Can I reduce days without losing equity. What happens if I retire early. What fees leave my practice. What debt exists above my shares. What distributions have actually been paid. Who determines the value of my stock. Can it be diluted. Can it be clawed back. When, how, and at what formula can I turn it into cash. What happens if the expected recapitalization never occurs.
Interestingly, ICON’s own website encourages prospective partners to ask many of these questions, including minimum employment terms, stock clawbacks, retirement liquidity, changes in ownership, autonomy, and whether the support organization actually reduces the dentist’s administrative burden. That is a useful reminder that rigorous due diligence is not anti DSO or anti DPO. It is simply good business.
The same transaction can also be rational for one dentist and irrational for another. A 63 year old owner who has reached financial independence, dislikes managing 40 employees, wants fewer administrative headaches, and values a planned transition may reasonably accept less maximum lifetime wealth for greater simplicity and reduced business risk. A 42 year old owner with little debt, strong margins, a capable team, and another 20 years of career runway may place a much higher value on retaining the stream of owner profits. Lifestyle, autonomy, stress, and time are real forms of value, but they should be measured separately from investment return rather than blended into a sales pitch.
The cleanest way to evaluate any DSO or DPO proposal is to model three paths with identical assumptions. Remain independent and sell later. Sell privately now. Partner with the group now. Compare after tax cash at closing, future clinical compensation, owner profits, management costs, debt exposure, distributions, dilution, work obligations, and probability weighted terminal equity value. Then separately account for the personal value of reduced administration, shared resources, recruiting support, professional community, and the ability to step away from the business.
The central lesson is not “sell” or “do not sell.” It is to stop letting the purchase multiple make the decision. Dentistry’s consolidation market is sophisticated enough that both the sales pitch and the criticism can sound convincing. The dentist’s defense is the same discipline used in the operatory. Diagnose before treating, separate evidence from emotion, understand the alternatives, and make sure the expected benefit is worth the risk being accepted.
If someone wants your practice, your future profits, and several more years of your labor, what would the numbers have to show before you would say yes?
Join the Conversation!